Xuelin (Steve) Wang
Lawyers
Filters
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing
BrainAurora Medical Technology HK$583 million IPO
We advised BrainAurora on its IPO and HKEX listing
Laekna HK$236 million placement of shares
We advised Laekna on the placement of new shares
Adagene $100 million at-the-market offering
We advised Adagene on the offering
H&H International CNY500 million bonds offering
The investment-grade notes are due 2027
HighTide Therapeutics HK$194.1 million IPO
We advised HighTide Therapeutics on its IPO and HKEX listing
WuXi XDC Cayman HK$3.68 billion IPO
The shares are listed on the HKEX
Genetron $126 million going-private transaction
We are separately advising Genetron and the special committee of its board on the transaction
Gracell Biotechnologies PIPE of ordinary shares and warrants
The company’s ADSs are listed on Nasdaq
Laekna HK$791 million IPO
We advised Laekna on its IPO and HKEX listing